NCI NCTN- Network Lead Academic Participating Site: USC

NCI NCTN-网络领导学术参与站点：USC

• 批准号: 8605629
• 负责人: Anthony Boutros El-Khoueiry
• 金额: $ 62.9万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-17 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8605629
• 关键词: Advisory Committees; Anatomy; Antineoplastic Agents; Appointment; Area; Award; Biological Markers; Blood; California; Cancer Center; Cancer Hospital; Caring; Cell physiology; Cholangiocarcinoma; Clinical; Clinical Research; Clinical Trials; Clinical Trials Design; Clinical Trials Network; Collection; Comprehensive Cancer Center; Conceptions; Correlative Study; County; County Hospitals; Dedications; Development; Doctor of Medicine; Doctor of Philosophy; Drug Kinetics; ERCC1 gene; Elderly; Enrollment; Ensure; Evaluation; Faculty; Freezing; Functional Imaging; Funding; Genes; Governing Board; Grant; Housing; Individual; Investigation; Laboratories; Lead; Leadership; Liquid substance; Los Angeles; Maintenance; Malignant Neoplasms; Malignant neoplasm of prostate; Malignant neoplasm of urinary bladder; Medical; Medical Staff; Medical center; Medicine; Mentors; Methodology; Minority; Modification; Molecular; Molecular Biology; Molecular Profiling; Molecular Target; Normal tissue morphology; Outcome; Pathway interactions; Patients; Pediatric Hospitals; Pharmaceutical Preparations; Pharmacodynamics; Physician Executives; Play; Positioning Attribute; Principal Investigator; Process; Quality of life; Recording of previous events; Recruitment Activity; Regimen; Research Activity; Research Design; Research Infrastructure; Research Personnel; Resistance; Resources; Role; Safety; Sampling; Site; Solid; Southwest Oncology Group; Specimen; Structure; System; Telomerase; Textiles; Therapy Clinical Trials; Toxic effect; Training; Translations; Treatment Effectiveness; Treatment Protocols; Tumor Tissue; USC/Norris Comprehensive Cancer Center and Hospital; United States; Universities; Variant; Voting; authority; base; cancer research center director; cancer therapy; chemotherapy; data acquisition; design; drug development; ethnic minority population; experience; improved; innovation; malignant stomach neoplasm; medical schools; member; named group; neoplastic cell; new technology; novel; organizational structure; patient population; pre-clinical; public health relevance; resistance mechanism; response; translational study; treatment strategy; tumor

DESCRIPTION (provided by applicant): The USC Norris Comprehensive Cancer Center first participated in the research activities of SWOG in 1987 and was initially funded in 1992. This five-year grant cycle has had increased administrative and academic participation, with maintenance of high clinical and correlative trial entry, commensurate with available SWOG funding and added resources from USC. The major emphases of the USC team are (a) to provide leadership across the NTCN to design and efficiently perform clinical trials evaluating the safety and efficacy of novel regimens or modifications of existing regimens; (b) to provide leadership in biomarker development and in integration of new technologies into NCTN trials, taking advantage of a systematic approach to collection, processing, and storage of blood, normal tissue, fresh or frozen tumor tissue, and other relevant biologic samples for molecular and pharmacologic studies; and (c) to evaluate cancer treatment regimens in special patient populations, such as rare cancers, the elderly and ethnic minorities. USC investigators have not only contributed extensively to SWOG trials but have demonstrated administrative/academic leadership, facilitating the translation of specific themes of investigation to SWOG. Recent SWOG trials evaluating the predictive role of ERCC1 expression in the outcome of patients with metastatic gastric cancer and the role of CTC enumeration and telomerase activity in prostate cancer highlight one aspect of the scientific leadership that USC investigators have provided in the NCI cooperative group system. They have also played an active role in NCI task forces and steering committees. As part of its dedication to cancer clinical research, USC has been successful in mentoring young investigators through the SWOG Young Investigator Awards (10) and has expanded its institutional training capabilities. Lastly, as a Network Lead Academic Participating Site, USC will continue to bring unique strengths to the NCI National Clinical Trials Network thanks to its strength in recruitment of minorities to clinical trials, accrual to rare cancers such as biliary and bladder cancers, and a well-developed clinical research infrastructure.

描述（由申请人提供）：南加州大学诺里斯综合癌症中心于 1987 年首次参与 SWOG 的研究活动，并于 1992 年首次获得资助。这个五年拨款周期增加了行政和学术参与，保持了较高的临床和相关试验进入率，与现有的 SWOG 资金和南加州大学的额外资源相称。 USC 团队的主要重点是 (a) 在整个 NTCN 中提供领导，以设计和有效地进行临床试验，评估新疗法或现有疗法修改的安全性和有效性； (b) 在生物标志物开发和将新技术融入 NCTN 试验方面发挥领导作用，利用系统方法收集、处理和储存血液、正常组织、新鲜或冷冻肿瘤组织以及其他相关生物样本以进行分子和药理学研究； (c) 评估特殊患者群体（例如罕见癌症、老年人和少数民族）的癌症治疗方案。南加州大学的研究人员不仅为 SWOG 试验做出了广泛贡献，而且展示了行政/学术领导力，促进了特定调查主题向 SWOG 的转化。最近的 SWOG 试验评估了 ERCC1 表达对转移性胃癌患者预后的预测作用，以及 CTC 计数和端粒酶活性在前列腺癌中的作用，凸显了 USC 研究人员在 NCI 合作小组系统中提供的科学领导力的一个方面。他们还在 NCI 工作组和指导委员会中发挥了积极作用。作为其致力于癌症临床研究的一部分，南加州大学已成功通过 SWOG 青年研究者奖 (10) 指导年轻研究者，并扩大了其机构培训能力。最后，作为网络领先的学术参与站点，南加州大学将继续为 NCI 国家临床试验带来独特的优势 该网络得益于其在招募少数群体参加临床试验、治疗胆道癌和膀胱癌等罕见癌症方面的优势，以及完善的临床研究基础设施。